Effect of Sitagliptin on Serum Irisin Levels in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
This study aimed to investigate the changes in serum irisin in patients with newly diagnosed type 2 diabetes mellitus (T2DM) following sitagliptin treatment.MethodsThirty-two patients with T2DM were treated with 100  mg/day sitagliptin for 16 weeks. Twenty age-, sex- and body mass index (BMI)-matched healthy subjects were enrolled as the control group. Irisin and metabolic parameters were measured at baseline and after treatment.ResultsPatients with T2DM had lower irisin levels than the controls (10.03  ± 2.06 vs. 13.06 ± 3.10 ng/ml,P 
Source: Diabetes Therapy - February 24, 2021 Category: Endocrinology Source Type: research

A Pragmatic Study of Basal and Mid-Mixture Insulins as Starter Insulins in Chinese Patients With Type 2 Diabetes: Observations From Long-Term, Real-World Experience
AbstractIntroductionAccording to Chinese guidelines, basal insulin (BI) or premixed insulins are recommended insulin starters following the failure of oral antihyperglycemic medication (OAM) in Chinese patients with type 2 diabetes (T2D). This pragmatic study investigated the long-term effectiveness, safety, and cost of add-on BI and mid-mixture insulin analog (MMI) regimens in Chinese patients with T2D.MethodsThis multicenter, open-label, pragmatic study randomized patients 1:1 to receive either BI or MMI with OAMs adjusted according to current standards of care. We evaluated the change in glycated hemoglobin (HbA1c) from...
Source: Diabetes Therapy - February 22, 2021 Category: Endocrinology Source Type: research

Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study
ConclusionSwitching to semaglutide from established GLP-1 analogue therapy improved HbA1c and body weight. Both equipotential and stepwise dosing initiation appear to be effective and well tolerated. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 22, 2021 Category: Endocrinology Source Type: research

What is Diabetes Remission?
(Source: Diabetes Therapy)
Source: Diabetes Therapy - February 20, 2021 Category: Endocrinology Source Type: research

Real-World Effectiveness and Safety of Insulin Glargine 300  U/mL in Patients with T2D Uncontrolled on NPH or Premixed Insulins as Part of Routine Clinical Practice in Bulgaria: ToUPGRADE Study
AbstractIntroductionThe aim of this study is to demonstrate the real-life effectiveness and safety of insulin glargine 300  U/mL (Gla-300) in patients with type 2 diabetes (T2D) previously uncontrolled on NPH ± prandial insulin or premixed insulins in routine clinical practice in Bulgaria.MethodsThis was a 24-week prospective, observational study performed in 40 inpatient and outpatient sites across the country.ResultsA total of 286 patients were included in the study. The mean age ( ± SD) was 61.2 ± 10.0 years with duration of diabetes of 11.64 ...
Source: Diabetes Therapy - February 19, 2021 Category: Endocrinology Source Type: research

Effects of Increasing Metformin Dose vs Adding/Switching to Dipeptidyl Peptidase-4 Inhibitors on Glycemic Control in Patients with Type 2 Diabetes
AbstractIntroductionMetformin has dose-dependent hypoglycemic effects on patients with type 2 diabetes (T2D). In Japan, metformin has been prescribed at lower doses than in Western countries. We analyzed the effect of increasing the metformin dose on glycemic control and compared it to a combination therapy with dipeptidyl peptidase-4 inhibitors (DPP-4i) and a replacement therapy with DPP-4i.MethodsThis is a cohort study using a Japanese claims database. Patients with T2D who had been initially treated with low-dose metformin ( ≥ 500 mg/day and 
Source: Diabetes Therapy - February 17, 2021 Category: Endocrinology Source Type: research

Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study
ConclusionSwitching to injectable semaglutide from any other GLP-1 RA was associated with significant improvements in glycaemic control and weight. Our findings support decision-making in clinical practice in patients with an indication to switch between GLP-1 RAs. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 17, 2021 Category: Endocrinology Source Type: research

Efficacy and Safety of Luseogliflozin in Patients with Type  2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial
ConclusionLuseogliflozin administration in patients with T2DM complicated by hepatic dysfunction was well tolerated, did not worsen the hepatic condition, and might even be beneficial to improve hepatic function, reduce liver fat, and attenuate liver injury and fibrosis.Trial RegistrationThis study was registered under the University Hospital Medical Information Network Clinical Trial Registry (UMIN-CTR) (No. UMIN000025808) and the Japan Registry of Clinical Trials (jRCT) (No. jRCTs021180017). (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 16, 2021 Category: Endocrinology Source Type: research

Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
AbstractIntroductionTo evaluate the efficacy of empagliflozin compared to pioglitazone in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM).MethodsIn this prospective randomized, double-blind, placebo-controlled trial, we assigned 106 patients with NAFLD and T2DM to receive empagliflozin 10  mg (n = 35), pioglitazone 30 mg (n = 34), or placebo (n = 37) for 24 weeks. Liver fat content and liver stiffness were measured using fibroscans. Body composition assessment was performed by dual-energy x-ray absorptiometry (DEXA) scans. The prima...
Source: Diabetes Therapy - February 14, 2021 Category: Endocrinology Source Type: research

Glucose Variability is Independently Correlated with Serum Level of Pigment Epithelium-Derived Factor in Type 2 Diabetes
ConclusionsThe results of this study suggest that MAGE may be independently correlated with elevations in serum PEDF level in patients with T2DM. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 13, 2021 Category: Endocrinology Source Type: research

Injection Technique Education in Patients with Diabetes Injecting Insulin into Areas of Lipohypertrophy: A Randomized Controlled Trial
ConclusionsProper IT, including learning to not inject into sites of LH, proper within- and between site rotation, needle reuse reduction, and the use of 4-mm, 32-G needles in Chinese patients injecting into sites of LH enables a safe reduction of TDD insulin while maintaining overall glycemic control.Trial RegistrationTrial registration: ChiCTR-IOR-16009270 in the Chinese Clinical Trials Registry. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 11, 2021 Category: Endocrinology Source Type: research

Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study
AbstractIntroductionThe glucagon-like peptide-1 receptor analogue (GLP-1RA) semaglutide is associated with improvements in glycaemia and cardiovascular risk factors in clinical trials. The aim of this study was to examine the real-world impact of semaglutide administered by injection in people with type 2 diabetes (T2D) across three secondary care sites in Wales.MethodsA retrospective evaluation of 189 patients with T2D initiated on semaglutide between January 2019 and June 2020 with at least one follow-up visit was undertaken.ResultsAt baseline, participants had a mean age of 61.1  years, mean glycated haemoglobin (H...
Source: Diabetes Therapy - February 9, 2021 Category: Endocrinology Source Type: research

Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin  + GLP-1 Receptor Agonist Combination Therapies
ConclusionAccording to this Delphi consensus, the addition of a GLP-1RA may be the best option to intensify BOT. The BI/GLP-1RA fixed combinations may increase compliance and optimize the advantages of each of these molecules. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 7, 2021 Category: Endocrinology Source Type: research

Impact of Intensive Glucose Control on Brain Health: Meta-Analysis of Cumulative Data from 16,584 Patients with Type 2 Diabetes Mellitus
ConclusionThis meta-analysis suggests that intensive glucose control in patients with type 2 diabetes can slow down cognitive decline, especially the decline in composite cognition and memory function. However, further studies are necessary to confirm the impact of strict glucose control on structural abnormalities in the brain and the risk of dementia. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 6, 2021 Category: Endocrinology Source Type: research

Effectiveness and Safety of Insulin Glulisine When Initiating Supplementary Prandial Insulin Treatment (SIT) in Insulin-Na ïve Patients with Type 2 Diabetes: The Observational IGLU-SIT Study
AbstractIntroductionThe IGLU-SIT study documented the effectiveness of initiating supplementary prandial insulin treatment (SIT) with insulin glulisine after failure of oral antidiabetic drugs alone in patients with type 2 diabetes (T2DM) in a real-world setting in Germany.MethodsThe IGLU-SIT study was an open-label, prospective, multicentre, non-interventional study with an observation period of 12  ± 1 months. The primary objective was to determine the proportion of patients reaching their pre-defined glycosylated haemoglobin (HbA1c) goal at 3, 6, 9 and 12 months. Selected secondary objecti...
Source: Diabetes Therapy - February 5, 2021 Category: Endocrinology Source Type: research

Movement is Improvement: The Therapeutic Effects of Exercise and General Physical Activity on Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
This study aimed to investigate and quantitatively summarize the literature regarding the therapeutic effects of exercise and general physical activity on glycemic control.MethodsA systematic review and meta-analysis of the literature on the therapeutic effects of exercise on glycemic control in patients with type 2 diabetes mellitus (type 2 DM) were conducted using electronic databases. Studies with an exercise intervention lasting more than 8  weeks were included. Both qualitative and quantitative analyses were performed. Qualitative data were presented narratively in table form. Quantitative analysis was performed ...
Source: Diabetes Therapy - February 5, 2021 Category: Endocrinology Source Type: research

Effectiveness and Safety of Switching Rapid-Acting Insulins to Insulin Glulisine in Patients with Diabetes: The Observational IGLU-S Study
AbstractIntroductionThe IGLU-S study assessed the effectiveness of insulin glulisine after switching from human insulin/other rapid-acting insulin analogues in patients with type 1 diabetes (T1DM) and type 2 diabetes (T2DM) in a real-world setting in Germany.MethodsOpen-label, prospective, multicentre, non-interventional study in Germany. The primary outcome was proportion of patients reaching pre-defined glycosylated haemoglobin A1c (HbA1c) goal at 3, 6, 9 and 12  months. Secondary outcomes included absolute changes in HbA1c, rate of hypoglycaemia and 7-point blood glucose profiles.ResultsOverall, 432 (55 T1DM, 377 T...
Source: Diabetes Therapy - February 5, 2021 Category: Endocrinology Source Type: research

Risk Factors for Albuminuria in Normotensive Older Adults with Type 2 Diabetes Mellitus and Normal Renal Function: A Cross-Sectional Study
AbstractIntroductionDiabetes mellitus (DM) is prevalent in developed and developing countries, including China. However, few studies have examined the potential risk factors for albuminuria in normotensive older adults with type 2 DM and normal renal function.MethodsWe recruited normotensive older adults ( ≥ 65 years) with type 2 DM and normal renal function from the First Affiliated Hospital of Soochow University from January to December 2019. We stratified participants according to their urine albumin to creatinine ratio (ACR) into the following groups: normal ACR (ACR1), microalbuminuria (ACR2 ), and macr...
Source: Diabetes Therapy - January 29, 2021 Category: Endocrinology Source Type: research

The Position of Gliclazide in the Evolving Landscapes and Disease Continuum of T2DM: A Collaborative Delphi Survey-Based Consensus from  India
ConclusionThe expert panel proposed consideration of monotherapy or dual therapy of gliclazide as an ideal choice in patients with T2DM because of its efficacy, long-term glycemic control, favorable renal outcomes, cardiovascular safety, and an optimal safety profile. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 28, 2021 Category: Endocrinology Source Type: research

Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study)
This study is a multicenter, prospective, randomized, open-label, blinded-endpoint, parallel-group trial. In total, 100 participants with T2D who have been treated with liraglutide (0.9 –1.8 mg/day in plan A) or dulaglutide (0.75 mg/week in plan B) for more than 12 weeks and have a glycated hemoglobin (HbA1c) level of 6.0–9.9% and a body mass index (BMI) of ≥ 22 kg/m2 will be randomized to either continue using their existing GLP-1 receptor agonist or switch to subcutaneous semaglutide once weekly for 24  weeks. Biochemical analysis, physical assessment, and a quality-o...
Source: Diabetes Therapy - January 24, 2021 Category: Endocrinology Source Type: research

What ’s in a Name? Redefining Type 2 Diabetes Remission
AbstractDiabetes remission is a concept that is marked by ample attention, but lack of unanimity. This opinion piece explores existing definitions of diabetes remission and proposes a contemporary and comprehensive framework to help define this clinical state. Type 2 diabetes remission is defined as a healthy clinical state characterized by achievement of HBA1c below the targeted level, maintained for at least 6  months, with or without continued use of lifestyle modification and/or metformin, provided that this is not due to complications, comorbid conditions or concomitant therapy.Diabetes Remission: Infographic (So...
Source: Diabetes Therapy - January 24, 2021 Category: Endocrinology Source Type: research

Skin Autofluorescence in Young Adult Offspring of Women with Type  1 Diabetes: A Cross-Sectional Case–Control Study
ConclusionSAF values did not differ between the young adult offspring of women with type  1 diabetes and offspring born to mothers without diabetes. Surprisingly, young adult women showed higher SAF values than men in both case and control groups. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 23, 2021 Category: Endocrinology Source Type: research

Baseline HbA1c Level Influences the Effect of Periodontal Therapy on Glycemic Control in People with Type 2 Diabetes and Periodontitis: A Systematic Review on Randomized Controlled Trails
ConclusionsPeriodontal therapy significantly contributed to glycemic control in T2DM patients, especially in patients with higher baseline HbA1c level. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 22, 2021 Category: Endocrinology Source Type: research

Application of Telemedicine in Diabetes Care: The Time is Now
This article offers an overview of existing applications that provide telemedicine diabetes care. Furthermore, it discusses potential ways to restructure and revolutionize diabetes outpatient care. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 20, 2021 Category: Endocrinology Source Type: research

Effects of the Once-Weekly DPP4 Inhibitor Omarigliptin on Glycemic Control in Patients with Type  2 Diabetes Mellitus on Maintenance Hemodialysis: A 24-Week Open-Label, Multicenter Randomized Controlled Study
ConclusionsOur data showed that omarigliptin was non-inferior to linagliptin in glycemic control. Omarigliptin is feasible for glycemic control in patients with T2DM on maintenance HD.Clinical Trials RegistrationUMIN000024284. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 20, 2021 Category: Endocrinology Source Type: research

A Retrospective Analysis of Therapeutic Inertia in Type 2 Diabetes Management Across a Diverse Population of Health Care Organizations in the USA
AbstractIntroductionIf their target glycated hemoglobin (HbA1c) is not achieved after 3  months, timely treatment intensification is recommended in people with type 2 diabetes to maintain glycemic control and minimize vascular complications. We retrospectively investigated potential therapeutic inertia in the management of type 2 diabetes in multiple health care organizations across t he USA.MethodsElectronic health records were analyzed from 22 American Medical Group Association (AMGA) health care organizations. Bolus insulin-na ïve patients with type 2 diabetes and HbA1c ≥ 8.0% (≥ 64&...
Source: Diabetes Therapy - January 18, 2021 Category: Endocrinology Source Type: research

Comparison of Patient-Led and Physician-Led Insulin Titration in Japanese Type 2 Diabetes Mellitus Patients Based on Treatment Distress, Satisfaction, and Self-Efficacy: The COMMIT-Patient Study
ConclusionSelf-measurement of blood glucose and self-titration of insulin enhanced the patients ’ self-efficacy without compromising their emotional distress or treatment satisfaction. Also, insulin self-titration was found to be safe and effective; it resulted in better glycemic control without severe hypoglycemia.Trial registrationUniversity Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) (registration number: UMIN000020316). (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 18, 2021 Category: Endocrinology Source Type: research

Effect of Orally Administered Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients with Type  2 Diabetes: The PIONEER 10 Randomized, Active-Controlled Trial
ConclusionOrally administered semaglutide 7 and 14  mg improved the patients’ HRQoL measured by the Japanese-specific DTR-QoL instrument versus dulaglutide 0.75 mg at week 52.Trial registrationClinicalTrials.gov NCT03015220. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 18, 2021 Category: Endocrinology Source Type: research

Long-Term Efficacy and Safety of Ultra Rapid Lispro (URLi) in Adults with Type  1 Diabetes: The PRONTO-T1D Extension
We present results of an additional 26-week treatment phase evaluating long-term efficacy and safety of URLi.MethodsIn this phase  3, treat-to-target study, subjects were randomized to double-blind mealtime URLi, lispro, or open-label postmeal URLi with insulin degludec or glargine for 26 weeks. Subjects in the double-blind URLi (n = 451) and lispro (n = 442) groups continued for another 26 weeks to assess long-term efficacy and safety.ResultsHbA1c increased marginally during the long-term maintenance period (week  26–52) in both groups to 7.47% (URLi) and 7.54% (lispro...
Source: Diabetes Therapy - January 17, 2021 Category: Endocrinology Source Type: research

Correction to: The Effects of Mobile-App-Based Low-Carbohydrate Dietary Guidance on Postprandial Hyperglycemia in Adults with Prediabetes
In the original article, The corresponding author details were missing. The corresponding author name is Q. Guo and his email address is guoqijp@gmail.com. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 17, 2021 Category: Endocrinology Source Type: research

Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin
ConclusionsEfficacy and safety (including immunogenicity) profiles of SAR-Asp are similar to those of NN-Asp over 52  weeks in adults with diabetes irrespective of prior type of mealtime insulin.Trial RegistrationClinicalTrials.gov identifier: NCT03211858. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 11, 2021 Category: Endocrinology Source Type: research

Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1  mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting
ConclusionOnce-weekly semaglutide 1  mg was projected to be a cost-effective treatment option from a healthcare payer perspective compared with empagliflozin 25 mg for the treatment of patients with type 2 diabetes in the UK setting. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 9, 2021 Category: Endocrinology Source Type: research

Correction to: Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
The original article can be found online. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 8, 2021 Category: Endocrinology Source Type: research

A Consideration of the Psychological Aspects to Managing Patients with Painful Diabetic Neuropathy: An Insight into Pain Management Services at a Tertiary Centre in the UK
AbstractPainful diabetic neuropathy (pDN) is characterised by both sensory and affective disturbances, suggesting a complex bidirectional relationship of neuropathic pain and mood disorders. Data on pDN indicate that neuropathic pain reduces quality of life, including mood and physical and social functioning. Depression and pain coping strategies such as catastrophising and social support predict pain severity. There is a significant and reciprocal relationship between depressed mood and increased pain. The key features of assessing people with neuropathic pain in relation to psychological aspects of their health are discu...
Source: Diabetes Therapy - December 26, 2020 Category: Endocrinology Source Type: research

Individualizing Time-in-Range Goals in Management of Diabetes Mellitus and Role of Insulin: Clinical Insights From a Multinational Panel
AbstractDiabetes mellitus is a global health concern associated with significant morbidity and mortality. Inadequate control of diabetes leads to chronic complications and higher mortality rates, which emphasizes the importance of achieving glycemic targets. Although glycated hemoglobin (HbA1c) is the gold standard for measuring glycemic control, it has several limitations. Therefore, in recent  years, along with the emergence of continuous glucose monitoring (CGM) technology, glycemic control modalities have moved beyond HbA1c. They encompass modern glucometrics, such as glycemic variability (GV) and time-in-range (T...
Source: Diabetes Therapy - December 26, 2020 Category: Endocrinology Source Type: research

Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type  2 Diabetes Mellitus: The Retrospective REALISE-DM Study
ConclusionsThis study supports switching T2DM patients on liraglutide or dulaglutide to injectable semaglutide to achieve further reductions in HbA1c and weight. Although a small number of GSEs occurred, semaglutide was well tolerated by the majority of the patients. (Source: Diabetes Therapy)
Source: Diabetes Therapy - December 26, 2020 Category: Endocrinology Source Type: research

New-Onset Diabetes in COVID-19: Time to Frame Its Fearful Symmetry
AbstractThere is increasing evidence that coronavirus disease 2019 (COVID-19) may lead to new-onset diabetes mellitus (DM). This may occur even in patients without predisposing factors for impaired glucose metabolism. Both impaired pancreatic insulin secretion and insulin resistance have been implicated as underlying mechanisms. Importantly, new-onset hyperglycaemia is associated with worse prognosis in patients with COVID-19. Indeed, its prognosis may be even more sinister than in patients with pre-existing DM. More research data and knowledge are currently being collected to improve our insights into this constellation a...
Source: Diabetes Therapy - December 26, 2020 Category: Endocrinology Source Type: research

Comparative Effectiveness of Switching From First-Generation Basal Insulin to Glargine  300 U/ml or Degludec 100 U/ml in Type 1 Diabetes: The RESTORE-1 Study
AbstractIntroductionFollowing pivotal trials, real-world evidence is important to assess the impact of new drugs in everyday clinical practice. The RESTORE-1 study aimed to compare effectiveness and safety of the second-generation basal insulins (2BI), i.e., insulin glargine 300  U/ml (Gla-300) vs. degludec 100 U/ml (IDeg-100), in type 1 diabetes (T1D).MethodsRetrospective, non-inferiority, multicenter study, based on electronic medical records. All patients switching to Gla-300 or IDeg-100 from first-generation basal insulins (1BI) were 1:1 propensity score matched (PSM). Changes during 6  months in Hb...
Source: Diabetes Therapy - December 22, 2020 Category: Endocrinology Source Type: research

Linear Projection of Estimated Glomerular Filtration Rate Decline with Canagliflozin and Implications for Dialysis Utilization and Cost in Diabetic Nephropathy
ConclusionUsing clinical trial data, canagliflozin treatment was projected to delay dialysis by approximately 13  years, which could translate to a substantial cost savings. More precise estimates should be investigated with considerations for nonlinear eGFR slope trajectory, competing risks, and patient characteristics.Trial RegistrationClinicalTrials.gov identifier, NCT02065791. (Source: Diabetes Therapy)
Source: Diabetes Therapy - December 18, 2020 Category: Endocrinology Source Type: research

Personality Traits, Metabolic Control and the Use of Insulin Pump Functions in Adults With Type 1 Diabetes: An Observational Single-Visit Study
AbstractIntroductionWhile a few studies have assessed the association between personality and metabolic outcomes in children and adolescents with type 1 diabetes (T1DM), there have been none in adults or in subjects treated with insulin pumps, and hypoglycaemic episodes have not been considered in these studies. The aim of this observational single-visit study was to assess the association between personality traits and metabolic control, hypoglycaemic episodes and insulin pump use in adult T1DM patients.MethodsData were obtained from 52 adults with T1DM treated in a tertiary care centre (no complications or  comorbid...
Source: Diabetes Therapy - December 15, 2020 Category: Endocrinology Source Type: research

The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type  2 Diabetes: The SURPASS Clinical Trials
AbstractGlucagon-like peptide  1 (GLP-1) based therapy is an established treatment option for the management of type 2 diabetes mellitus (T2DM) and is recommended early in the treatment algorithm owing to glycaemic efficacy, weight reduction and favourable cardiovascular outcomes. Glucose-dependent insulinotropic polypeptide ( GIP), on the other hand, was thought to have no potential as a glucose-lowering therapy because of observations showing no insulinotropic effect from supraphysiological infusion in people with T2DM. However, emerging evidence has illustrated that co-infusion of GLP-1 and GIP has a synergeti...
Source: Diabetes Therapy - December 15, 2020 Category: Endocrinology Source Type: research

Latin American Expert Consensus for Comprehensive Management of Type 2 Diabetes from a Metabolic –Cardio–Renal Perspective for the Primary Care Physician
AbstractGrowing scientific evidence from studies on type 2 diabetes (T2D) has recently led to a better understanding of the associated metabolic –cardio–renal risks. The large amount of available information makes it essential to have a practical guide that summarizes the recommendations for the initial management of patients with T2D, integrating different aspects of endocrinology, cardiology, and nephrology. The expert consensus presen ted here does not attempt to summarize all the evidence in this regard but rather attempts to define practical summary recommendations for the primary care physician to improve...
Source: Diabetes Therapy - December 15, 2020 Category: Endocrinology Source Type: research

Insulinization in T2DM with Basal Analogues During COVID-19 Pandemic: Expert Opinion  from an Indian Panel
AbstractThe ongoing global pandemic of the coronavirus disease 2019 (COVID-19) has placed a severe strain on the management of chronic conditions like diabetes. Optimal glycemic control is always important, but more so in the existing environment of COVID-19. In this context, timely insulinization to achieve optimal glycemic control assumes major significance. However, given the challenges associated with the pandemic like restrictions of movement and access to healthcare resources, a simple and easy way to initiate and optimize insulin therapy in people with uncontrolled diabetes is required. With this premise, a group of...
Source: Diabetes Therapy - December 12, 2020 Category: Endocrinology Source Type: research

Comparative Efficacy of Dual and Single Initiation of Add-On Oral Antihyperglycemic Agents in Type 2 Diabetes Uncontrolled on Metformin Alone: A Systematic Literature Review and Network Meta-Analysis
AbstractIntroductionCurrent guidelines recommend adding an oral antihyperglycemic agent (AHA) to metformin in patients with type 2 diabetes mellitus (T2DM) uncontrolled on metformin. Recent randomized clinical trials (RCTs) have demonstrated that adding dual AHAs instead of a single AHA provided more effective glycemic control. However, the comparative efficacy of approved single and dual initiation strategies is unknown. Therefore, we conducted a Bayesian network meta-analysis to compare the efficacy of dual and single add-on oral AHAs in patients uncontrolled on metformin.MethodsA systematic literature review of RCTs was...
Source: Diabetes Therapy - December 12, 2020 Category: Endocrinology Source Type: research

Improving HbA1c Control in Type  1 or Type 2 Diabetes Using Flash Glucose Monitoring: A Retrospective Observational Analysis in Two German Centres
AbstractIntroductionThe aim of this study was to evaluate change in laboratory-measured HbA1c in patients with either type  1 diabetes (T1D) or type 2 diabetes (T2D) on insulin therapy following initiation of the FreeStyle Libre™ flash glucose monitoring system.MethodsThis was a retrospective observational study on adults with T1D or T2D on insulin, who were started on the FreeStyle Libre system as part of standard care. HbA1c was recorded at initiation and at 3-month intervals thereafter.ResultsThe analysis included 131 patients with T1D and 176 patients with T2D on insulin. Mean HbA1c decreased significan...
Source: Diabetes Therapy - December 11, 2020 Category: Endocrinology Source Type: research

Smart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type  1 Diabetes in Sweden: A Cost-Effectiveness Analysis
ConclusionsUse of smart insulin pens was projected to improve clinical outcomes at lower costs relative to standard care in a Swedish T1D population and represents a good use of healthcare resources in Sweden. (Source: Diabetes Therapy)
Source: Diabetes Therapy - December 11, 2020 Category: Endocrinology Source Type: research

Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57)
AbstractIntroductionThere are limited real-world data on the prescribing of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for patients with type 2 diabetes mellitus (T2DM).MethodsThis was a retrospective analysis of the CoDiC ® database of the Japan Diabetes Clinical Data Management Study Group (JDDM). Demographic and clinical characteristics, concomitant treatment patterns, and GLP-1 RA treatment persistence or modification in patients with T2DM initiating GLP-1 RA therapy were evaluated.ResultsThe analysis included 932 eligible patients with T2DM who had their first GLP-1 RA prescription (index date) between ...
Source: Diabetes Therapy - December 9, 2020 Category: Endocrinology Source Type: research

Nutritional Status of Pediatric Patients with Type 1 Diabetes Mellitus from Northeast Poland: A Case-Control Study
AbstractIntroductionA significant increase in the incidence of overweight and obesity is observed among children and adolescents. This problem began to occur not only in healthy populations, but also among young diabetics. The aim of the study was to assess the nutritional status of children and adolescents with type 1 diabetes mellitus (T1DM) compared to those in a control group of healthy subjects as well as to determine the influence of the type of insulin therapy used.MethodsThe case-control study included 169 people aged 9 –15 years. The study group (n = 85) consisted of Polish children with T1DM, ...
Source: Diabetes Therapy - December 8, 2020 Category: Endocrinology Source Type: research

Inpatient Hyperglycemia Management and COVID-19
AbstractDiabetes is one of the most common comorbidities in hospitalized patients with coronavirus disease 2019 (COVID-19). Inpatient hyperglycemia during this pandemic has been associated with worse outcomes, so it is mandatory to implement effective glycemic control treatment approaches for inpatients with COVID-19. The shortage of personal protective equipment, the need to prevent staff exposure, or the fact that many of the healthcare professionals might be relatively unfamiliar with the management of hyperglycemia may lead to worse glycemic control and, consequently, a worse prognosis. In order to reduce these barrier...
Source: Diabetes Therapy - December 5, 2020 Category: Endocrinology Source Type: research

Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type  2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model
ConclusionModel results suggest that adding canagliflozin 100  mg to SoC can improve patient outcomes while reducing overall net costs from the NHS perspective in England.Trial RegistrationClinicalTrials.gov identifier, NCT02065791. (Source: Diabetes Therapy)
Source: Diabetes Therapy - December 2, 2020 Category: Endocrinology Source Type: research